Versions
- 2026-01-26 (2)
- 2025-09-11 (1)
Keywords
Breast cancer
Female sexual function
Female sexual dysfunction
Tamoxifen
Categories
How to Cite
Abstract
Introduction: women undergoing treatment with tamoxifen for breast cancer may experience alterations in sexual function, including dysfunctions in desire, arousal, lubrication, and sexual satisfaction, which in turn significantly affect their quality of life.
Objective: to determine the effect of tamoxifen treatment on the sexual function of women with breast cancer during the period 2013–2023.
Methodology: the study employed a qualitative, retrospective documentary analysis in the form of a scoping review.
Results: this review revealed that women undergoing tamoxifen therapy for breast cancer experience various forms of sexual dysfunction, including female sexual interest/arousal disorder, genito-pelvic pain/penetration disorder, and female orgasmic disorder. Furthermore, it was observed that women receiving both chemotherapy and tamoxifen exhibited a greater negative effect on sexual function compared to those treated with tamoxifen alone.
Conclusion: women undergoing chemotherapy or ovarian function suppression in combination with tamoxifen experience a greater negative effect on sexual function compared to those receiving tamoxifen monotherapy.
References
1. Palmero Picazo J, Lassard Rosenthal J, Juárez Aguilar LA, Medina Núñez CA. Cáncer de mama: una visión general. Acta Médica Grupo Ángeles [Internet]. 2021 [citado el 30 de diciembre de 2024];19(3):354–60. Disponible en: https://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1870-72032021000300354
2. Organización Mundial de la Salud (OMS). Cáncer de mama, datos y cifras. [Internet]. 2022 [citado el 30 de diciembre de 2024]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/breast-cancer
3. Globlal cancer observatory. Statistics al Chile. 2022 [citado el 30 de diciembre de 2024]. Disponible en: https://gco.iarc.who.int/media/globocan/factsheets/populations/152-chile-fact-sheet.pdf
4. Icaza G, Núñez L, Bugueño H. Epidemiological analysis of breast cancer mortality in women in Chile. Rev Med Chil [Internet]. 2017;145(1):106–14. Disponible en: http://dx.doi.org/10.4067/S0034-98872017000100014
5. Merino-Pereira G. Puesta al día en cáncer de mama en Chile. Rev Chil Obstet Ginecol [Internet]. 2023;88(5). Disponible en: http://dx.doi.org/10.24875/rechog.m23000063
6. Rodríguez MC. Impacto psicológico frente al diagnóstico de cáncer de mama: primeras reacciones emocionales. Index de Enfermería [Internet]. 2017 [citado el 30 de diciembre de 2024];26(4):299–302. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1132-12962017000300015&lng=es&tlng=es
7. Asociación Americana de Psiquiatría. Manual Diagnóstico y Estadístico de los Trastornos Mentales DSM-5. 2013 [citado el 30 de diciembre de 2024]. Medica Panamericana. Disponible en: https://www.federaciocatalanatdah.org/wp-content/uploads/2018/12/dsm5manualdiagnsticoyestadisticodelostrastornosmentales-161006005112.pdf
8. Valverde-Ampai W, Palma-Rozas G, Conei D, Marzuca-Nassr GN, Medina-González P, Escobar-Cabello M, et al. Efectos del tratamiento con quimioterapia y radioterapia concomitante sobre los volúmenes pulmonares en mujeres con cáncer de mama en Talca, Chile. Rev Fac Med Univ Nac Colomb [Internet]. 2020 Apr 8 [cited 2025 May 7];68(2):222–8. Available from: http://dx.doi.org/10.15446/revfacmed.v68n2.73402
9. Patel P, Jacobs TF. Tamoxifen. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532905/
10. Brufsky AM, Dickler MN. Estrogen receptor-positive breast cancer: Exploiting signaling pathways implicated in endocrine resistance. Oncologist [Internet]. 2018 May;23(5):528–39. Available from: http://dx.doi.org/10.1634/theoncologist.2017-0423
11. Chang M. Tamoxifen resistance in breast cancer. Biomol Ther (Seoul) [Internet]. 2012 May;20(3):256–67. Available from: http://dx.doi.org/10.4062/biomolther.2012.20.3.256
12. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst [Internet]. 2003 Apr 2;95(7):526–32. Available from: http://dx.doi.org/10.1093/jnci/95.7.526
13. Kloos I, Delaloge S, Pautier P, Di Palma M, Goupil A, Duvillard P, et al. Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. Int J Gynecol Cancer [Internet]. 2002 Sep [cited 2025 May 5];12(5):496–500. Available from: http://dx.doi.org/10.1046/j.1525-1438.2002.01134.x
14. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet [Internet]. 2003 Jan 25 [cited 2025 May 5];361(9354):296–300. Available from: http://dx.doi.org/10.1016/S0140-6736(03)12342-2
15. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst [Internet]. 1994 Apr 6 [cited 2025 May 5];86(7):527–37. Available from: http://dx.doi.org/10.1093/jnci/86.7.527
16. Hendrick A, Subramanian VP. Tamoxifen and thromboembolism. JAMA [Internet]. 1980 Feb 8 [cited 2025 May 5];243(6):514–5. Available from: http://dx.doi.org/10.1001/jama.1980.03300320012005
17. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol [Internet]. 1999 Sep [cited 2025 May 5];17(9):2659–69. Available from: http://dx.doi.org/10.1200/JCO.1999.17.9.2659
18. Ganz PA. Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life. J Natl Cancer Inst Monogr [Internet]. 2001 [cited 2025 May 5];2001(30):130–4. Available from: http://dx.doi.org/10.1093/oxfordjournals.jncimonographs.a003450
19. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med [Internet]. 1989 Feb 23 [cited 2025 May 5];320(8):479–84. Available from: http://dx.doi.org/10.1056/NEJM198902233200802
20. Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med [Internet]. 1991 Sep;151(9):1842–7. Available from: https://doi.org/10.1001/archinte.1991.00400090120021?locatt=mode:legacy
21. Ganz PA, Rowland JH, Meyerowitz BE, Desmond KA. Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. In: Recent Results in Cancer Research [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 1998 [cited 2025 May 5]. p. 396–411. (Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer; vol. 152). Available from: http://dx.doi.org/10.1007/978-3-642-45769-2_38
22. Ribi K, Luo W, Walley BA, Burstein HJ, Chirgwin J, Ansari RH, et al. Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. Breast Cancer Res Treat [Internet]. 2020;181(2):347–59. Disponible en: http://dx.doi.org/10.1007/s10549-020-05622-5
23. Fielder R. Sexual Functioning. In: Encyclopedia of Behavioral Medicine [Internet]. New York, NY: Springer New York; 2013 [cited 2025 May 7]. p. 1774–7. Available from: http://dx.doi.org/10.1007/978-1-4419-1005-9_668
24. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther [Internet]. 2000 Apr [cited 2025 May 7];26(2):191–208. Available from: http://dx.doi.org/10.1080/009262300278597
25. Davis SR. Sexual dysfunction in women. N Engl J Med [Internet]. 2024 Aug 22 [cited 2025 May 7];391(8):736–45. Available from: http://dx.doi.org/10.1056/NEJMcp2313307
26. López Rubio MA, Tárraga López PJ, Melero López JA, Moya Plaza A. Salud sexual en mujeres con cáncer de mama tratadas con Tamoxifeno. J Negat No Posit Results [Internet]. 2020 [citado el 30 de diciembre de 2024];5(12):1528–37. Disponible en: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S2529-850X2020001200007
27. Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA, et al. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet [Internet]. 2016;387(10021):857–65. Disponible en: http://dx.doi.org/10.1016/S0140-6736(15)01169-1
28. Wani SQ, Khan T, Wani SY, Teli MA, Khan NA, Mir LR, et al. Breast specific functional and symptom analysis in female breast cancer survivors. J Cancer Res Ther [Internet]. 2018;14(3):521–6. Disponible en: http://dx.doi.org/10.4103/0973-1482.165867
29. Ganz PA, Petersen L, Bower JE, Crespi CM. Impact of adjuvant endocrine therapy on quality of life and symptoms: Observational data over 12 months from the mind-body study. J Clin Oncol [Internet]. 2016;34(8):816–24. Disponible en: http://dx.doi.org/10.1200/JCO.2015.64.3866
30. Ribi K, Luo W, Bernhard J, Francis PA, Burstein HJ, Ciruelos E, et al. Adjuvant tamoxifen plus Ovarian Function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of Ovarian Function trial. J Clin Oncol [Internet]. 2016;34(14):1601–10. Disponible en: http://dx.doi.org/10.1200/JCO.2015.64.8675
31. Bernhard J, Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol [Internet]. 2015;16(7):848–58. Disponible en: http://dx.doi.org/10.1016/S1470-2045(15)00049-2
32. Tevaarwerk AJ, Wang M, Zhao F, Fetting JH, Cella D, Wagner LI, et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol [Internet]. 2014;32(35):3948–58. Disponible en: http://dx.doi.org/10.1200/JCO.2014.55.6993
33. Irarrázaval O ME, Gaete G L. Antidepressants agents in breast cancer patients using tamoxifen: review of basic and clinical evidence. Rev Med Chil [Internet]. 2016;144(10):1326–35. Disponible en: http://dx.doi.org/10.4067/S0034-98872016001000013
34. Alonso Sánchez AV, Martínez Ortiz MJ, Piñero Madrona A, Álamo González C, Salgado Ascencio R, Cerezuela P. Prescripción conjunta de antidepresivos y tamoxifeno: una cuestión a tener en cuenta. Rev Senol Patol Mamar [Internet]. 2013;26(4):134–7. Disponible en: http://dx.doi.org/10.1016/j.senol.2013.10.003
35. Berrospi-Reyna S, Herencia-Souza M, Soto Tarazona A. Prevalencia y factores asociados a la sintomatología depresiva en mujeres con cáncer de mama en un hospital público de Lima, Perú. Acta médica perú [Internet]. 2017;34(2):95–100. Disponible en: http://dx.doi.org/10.35663/amp.2017.342.316
36. Young-McCaughan S. Sexual functioning in women with breast cancer after treatment with adjuvant therapy. Cancer Nurs [Internet]. 1996;19(4):308–19. Disponible en: http://dx.doi.org/10.1097/00002820-199608000-00007
37. Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst [Internet]. 2002;94(1):39–49. Disponible en: http://dx.doi.org/10.1093/jnci/94.1.39
38. Broeckel JA, Thors CL, Jacobsen PB, Small M, Cox CE. Sexual functioning in long-term breast cancer survivors treated with adjuvant chemotherapy. Breast Cancer Res Treat [Internet]. 2002;75(3):241–8. Disponible en: http://dx.doi.org/10.1023/a:1019953027596
39. Ganz PA, Greendale GA, Petersen L, Kahn B, Bower JE. Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol [Internet]. 2003;21(22):4184–93. Disponible en: http://dx.doi.org/10.1200/JCO.2003.04.196
40. Yoon J, Malin JL, Tisnado DM, Tao ML, Adams JL, Timmer MJ, et al. Symptom management after breast cancer treatment: is it influenced by patient characteristics? Breast Cancer Res Treat [Internet]. 2008;108(1):69–77. Disponible en: http://dx.doi.org/10.1007/s10549-007-9580-1
41. Barni S, Mondin R. Sexual dysfunction in treated breast cancer patients. Ann Oncol [Internet]. 1997;8(2):149–53. Disponible en: http://dx.doi.org/10.1023/a:1008298615272
42. Burwell SR, Case LD, Kaelin C, Avis NE. Sexual problems in younger women after breast cancer surgery. J Clin Oncol [Internet]. 2006;24(18):2815–21. Disponible en: http://dx.doi.org/10.1200/JCO.2005.04.2499
43. Vaidakis D, Panoskaltsis T, Poulakaki N, Kouloura A, Kassanos D, Papadimitriou G, et al. Female sexuality after female cancer treatment: a clinical issue. Eur J Gynaecol Oncol. 2014;35(6):635–40.
44. Santos Miranda TR, Rojas Rodriguez NT, Ferraz V de S, Gomes de Souza Pegorare AB. Avaliação da sexualidade, qualidade de vida e capacidade funcional em mulheres sobreviventes do câncer de mama. Multitemas [Internet]. 2022;87–106. Disponible en: http://dx.doi.org/10.20435/multi.v27i65.3373
45. Cobo-Cuenca AI, Martín-Espinosa NM, Sampietro-Crespo A, Rodríguez-Borrego MA, Carmona-Torres JM. Sexual dysfunction in Spanish women with breast cancer. PLoS One [Internet]. 2018;13(8): e0203151. Disponible en: http://dx.doi.org/10.1371/journal.pone.0203151
46. Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol [Internet]. 1999;17(5):1488–92. Disponible en: http://dx.doi.org/10.1200/JCO.1999.17.5.1488
47. Duric V, Stockler M. Preferencias de las pacientes por la quimioterapia adyuvante en el cáncer de mama en etapa temprana: Una revisión de sus ventajas. Lancet Oncol. 2001;2:691–697. doi: 10.1016/S1470-2045(01)00559-9
48. Duric VM, Fallowfield LJ, Saunders C, et al. Preferencias de las pacientes por la terapia endocrina adyuvante en el cáncer de mama en etapa temprana: ¿Qué la hace útil? Br J Cancer. 2005;93:1319–1323. doi: 10.1038/sj.bjc.6602874
49. Sánchez F, Pérez Conchillo M, Borrás Valls JJ, Gómez Llorens O, Aznar Vicente J, Caballero Martín de Las Mulas A. Aten Primaria [Internet]. 2004;34(6):286–92. Disponible en: http://dx.doi.org/10.1016/s0212-6567(04)79497-4
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright (c) 2025 Contemporary Midwifery Journal